Tempus AI, Inc. (TEM)
TEM Q2 Loss Narrower Than Expected, Revenues Beat, Stock Up
Tempus AI climbs 6.6% after its second-quarter loss narrows, revenues beat estimates and 2026 sales guidance rises on diagnostics and data growth.
Tempus AI, Inc. (TEM) Q2 2026 Earnings Call Transcript
Tempus AI, Inc. (TEM) Q2 2026 Earnings Call Transcript
Compared to Estimates, Tempus (TEM) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Tempus (TEM) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Tempus AI (TEM) Reports Q2 Loss, Beats Revenue Estimates
Tempus AI (TEM) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.22 per share a year ago.
Tempus AI Stock Before Q2 Earnings Release: To Buy, Hold or Sell?
TEM heads into Q2 earnings with 21.3% expected revenue growth, strong diagnostics demand and AI deals, but near-term margin pressure remains.
Tempus AI (TEM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Tempus (TEM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tempus AI: Building Ultimate Healthcare Data Dominance
Tempus AI, Inc. earns a Strong Buy rating due to its transformation into a healthcare data giant with high-margin, rapidly growing data services. TEM's Q1 2026 data segment revenue surged 40% YoY to $87M, with robust bookings and visibility, positioning the segment for $500M+ revenue in 2026. MRD testing volume rose 500% YoY, driven by a highly sensitive, reimbursed test partnership with Personalis, fueling valuable data acquisition for pharma clients.
Tempus AI: Buy On Diagnostics Momentum And AI Platform Expansion
Tempus receives a Buy rating, leveraging a unique AI-driven diagnostics and data platform with expanding FDA-approved offerings. Recent FDA approval for xT CDx's tumor-only indication and the upcoming xH assay broaden TEM's clinical reach and addressable markets. AI-powered Lens and Next platforms drive adoption among top biopharma and improve clinical outcomes, reinforcing TEM's data flywheel and competitive moat.
Should You Retain Tempus AI Stock In Your Portfolio Now?
TEM's diagnostics growth and expanding data deals support momentum, but sizable GAAP losses and execution challenges could keep shares volatile.
Tempus AI: AI Precision Medicine With A Moat
Tempus AI trades at multi-year lows despite proprietary data advantages and robust AI-driven precision medicine capabilities. The company leverages 500+ petabytes of unique multimodal healthcare data inaccessible to generic AI models. With a market cap under $9B and trading at ~4.5x forward sales, the stock's valuation is compelling given management's 25% annual growth target versus more conservative analyst estimates.
Tempus AI: The Compression Has Outrun The Business - Upgrading To Buy
Tempus AI (TEM) now offers an attractive risk-reward setup, with valuations normalized to ~5.7x forward revenue and improved visibility on durable, high-margin revenues. Organic growth remains robust at ~25% for 2026, with no adverse revisions for 2027–2028, and margin mix shifting toward higher-margin Data and Applications segments. Adjusted operating loss has narrowed significantly, and TEM is approaching operating breakeven, supporting the SaaS-like trajectory critical for long-term value.
Tempus AI: A Unique AI Business Model With Asymmetric Upside
Tempus AI is rated Strong Buy, leveraging a unique data moat and network effect in healthcare AI. TEM's Diagnostics and Data & Applications segments drive robust 36% YoY revenue growth, with expanding gross margins and deepening pharma partnerships. Massive proprietary datasets (45M+ de-identified records, 500+ PB) underpin AI tools, SaaS revenue, and cross-selling opportunities, creating high barriers to entry.
